FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979596197> ?p ?o ?g. }

• W2979596197 endingPage "S482" @default.
• W2979596197 startingPage "S482" @default.
• W2979596197 abstract "INTRODUCTION: Risankizumab (RZB), an IL-23 p19 inhibitor, has shown safety and efficacy in inducing clinical remission in patients with Crohn’s disease (CD) in a Phase 2 study. 1 Here we assessed early symptom improvement during the randomized, double-blind, placebo-controlled induction phase of the trial. METHODS: This Phase 2 study enrolled adult patients with moderate-to-severe CD with a Crohn’s Disease Activity Index (CDAI) of 220–450, ulcers in the ileum and/or colon, and a Crohn’s Disease Endoscopic Index of Severity (CDEIS) ≥7 (≥4 for patients with isolated ileitis) assessed by ileocolonoscopy confirmed by a blinded central reader. Patients were randomized 1:1:1 to receive intravenous RZB (200 mg or 600 mg) or placebo at Weeks 0, 4, and 8. Endpoints examined in this post hoc analysis included changes from baseline at Weeks 2, 4, 8, and 12 in CDAI, average daily stool frequency (SF) and average daily abdominal pain score (AP) for all patients with available data, and newly defined clinical remission at Week 12, based on symptom improvement, defined as SF ≤ 2.8 and AP ≤1, both not worse than baseline, in patients with baseline SF ≥ 4 or AP ≥2. Continuous endpoints were analyzed using observed case; non-responder imputation was used for missing data of binary endpoints. Statistical comparisons of median change were based on Wilcoxon rank sum test. RESULTS: 121 patients were randomized in the induction phase. Baseline characteristics were similar among treatment arms.1 Mean (SD) disease duration at baseline was 13.4 (9.4) years; 94.2% of patients received previous anti-TNF therapy. Significant improvements in CDAI and AP were observed with RZB (600 mg) versus placebo as early as Week 2 and in SF at Week 8 (Table 1). The proportion of patients with clinical remission based on symptom improvement was significantly higher in the 600 mg RZB group versus placebo at Week 12 (23.7% versus 6.1%; P < 0.05), supporting the previously reported superiority of RZB versus placebo for inducing CDAI remission at Week 12 (36.6% of 600 mg RZB versus 15% of placebo; P < 0.05). CONCLUSION: RZB induction treatment was associated with significant early improvements in clinical symptoms and disease activity in a highly refractory patient population with moderately to severely active CD." @default.
• W2979596197 created "2019-10-18" @default.
• W2979596197 creator A5009052837 @default.
• W2979596197 creator A5014100389 @default.
• W2979596197 creator A5020766461 @default.
• W2979596197 creator A5023978252 @default.
• W2979596197 creator A5024119946 @default.
• W2979596197 creator A5029428855 @default.
• W2979596197 creator A5032150391 @default.
• W2979596197 creator A5032480207 @default.
• W2979596197 creator A5040354010 @default.
• W2979596197 creator A5041247421 @default.
• W2979596197 creator A5048464948 @default.
• W2979596197 creator A5050963621 @default.
• W2979596197 creator A5057899912 @default.
• W2979596197 creator A5063415172 @default.
• W2979596197 creator A5065356435 @default.
• W2979596197 date "2019-10-01" @default.
• W2979596197 modified "2023-10-17" @default.
• W2979596197 title "834 Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Analysis From a Phase 2 Study" @default.
• W2979596197 doi "https://doi.org/10.14309/01.ajg.0000592872.28570.f3" @default.
• W2979596197 hasPublicationYear "2019" @default.
• W2979596197 type Work @default.
• W2979596197 sameAs 2979596197 @default.
• W2979596197 citedByCount "0" @default.
• W2979596197 crossrefType "journal-article" @default.
• W2979596197 hasAuthorship W2979596197A5009052837 @default.
• W2979596197 hasAuthorship W2979596197A5014100389 @default.
• W2979596197 hasAuthorship W2979596197A5020766461 @default.
• W2979596197 hasAuthorship W2979596197A5023978252 @default.
• W2979596197 hasAuthorship W2979596197A5024119946 @default.
• W2979596197 hasAuthorship W2979596197A5029428855 @default.
• W2979596197 hasAuthorship W2979596197A5032150391 @default.
• W2979596197 hasAuthorship W2979596197A5032480207 @default.
• W2979596197 hasAuthorship W2979596197A5040354010 @default.
• W2979596197 hasAuthorship W2979596197A5041247421 @default.
• W2979596197 hasAuthorship W2979596197A5048464948 @default.
• W2979596197 hasAuthorship W2979596197A5050963621 @default.
• W2979596197 hasAuthorship W2979596197A5057899912 @default.
• W2979596197 hasAuthorship W2979596197A5063415172 @default.
• W2979596197 hasAuthorship W2979596197A5065356435 @default.
• W2979596197 hasBestOaLocation W29795961971 @default.
• W2979596197 hasConcept C126322002 @default.
• W2979596197 hasConcept C142724271 @default.
• W2979596197 hasConcept C168563851 @default.
• W2979596197 hasConcept C204787440 @default.
• W2979596197 hasConcept C27081682 @default.
• W2979596197 hasConcept C2779134260 @default.
• W2979596197 hasConcept C2779280984 @default.
• W2979596197 hasConcept C2780941987 @default.
• W2979596197 hasConcept C2780955771 @default.
• W2979596197 hasConcept C30036603 @default.
• W2979596197 hasConcept C67761136 @default.
• W2979596197 hasConcept C71924100 @default.
• W2979596197 hasConcept C90924648 @default.
• W2979596197 hasConceptScore W2979596197C126322002 @default.
• W2979596197 hasConceptScore W2979596197C142724271 @default.
• W2979596197 hasConceptScore W2979596197C168563851 @default.
• W2979596197 hasConceptScore W2979596197C204787440 @default.
• W2979596197 hasConceptScore W2979596197C27081682 @default.
• W2979596197 hasConceptScore W2979596197C2779134260 @default.
• W2979596197 hasConceptScore W2979596197C2779280984 @default.
• W2979596197 hasConceptScore W2979596197C2780941987 @default.
• W2979596197 hasConceptScore W2979596197C2780955771 @default.
• W2979596197 hasConceptScore W2979596197C30036603 @default.
• W2979596197 hasConceptScore W2979596197C67761136 @default.
• W2979596197 hasConceptScore W2979596197C71924100 @default.
• W2979596197 hasConceptScore W2979596197C90924648 @default.
• W2979596197 hasIssue "1" @default.
• W2979596197 hasLocation W29795961971 @default.
• W2979596197 hasLocation W29795961972 @default.
• W2979596197 hasOpenAccess W2979596197 @default.
• W2979596197 hasPrimaryLocation W29795961971 @default.
• W2979596197 hasRelatedWork W2033482244 @default.
• W2979596197 hasRelatedWork W2109412611 @default.
• W2979596197 hasRelatedWork W2116289754 @default.
• W2979596197 hasRelatedWork W2131386362 @default.
• W2979596197 hasRelatedWork W2911805811 @default.
• W2979596197 hasRelatedWork W2979596197 @default.
• W2979596197 hasRelatedWork W2992015492 @default.
• W2979596197 hasRelatedWork W4205359509 @default.
• W2979596197 hasRelatedWork W4309590924 @default.
• W2979596197 hasRelatedWork W4316078287 @default.
• W2979596197 hasVolume "114" @default.
• W2979596197 isParatext "false" @default.
• W2979596197 isRetracted "false" @default.
• W2979596197 magId "2979596197" @default.
• W2979596197 workType "article" @default.